Oragenics Reports $2.2 Million Net Loss in Q1 2026, No Revenue Generated

Oragenics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $2.2 million, a slight improvement from the $2.22 million loss recorded in the same period of 2025. The company did not generate any revenue during this quarter, consistent with its performance in the previous year. Total operating expenses increased to $2.26 million, up 11.3% from $2.03 million in the prior year, primarily driven by a significant rise in research and development costs, which surged by 89% to $645,470. This increase reflects heightened external professional and consulting expenses related to the advancement of its lead product candidate, ONP-002, aimed at treating mild traumatic brain injury.

In terms of financial position, Oragenics reported total assets of $7.49 million as of March 31, 2026, down from $10.07 million at the end of 2025. The decrease in total assets was largely attributed to a reduction in cash and cash equivalents, which rose to $6.1 million from $4.4 million, following the maturity of a short-term investment. Current liabilities also decreased to $1.31 million from $1.79 million, primarily due to lower accounts payable and accrued expenses. Stockholders' equity fell to $6.18 million from $8.28 million, reflecting the ongoing net losses and the impact of stock transactions during the quarter.

Operationally, Oragenics is advancing its clinical trial for ONP-002, with the Phase IIa trial currently underway in Australia. As of April 20, 2026, the company reported that eight doses had been administered to two patients, with enrollment progressing at Mackay Base Hospital. The company plans to initiate U.S.-based Phase IIb trials following the completion of the Australian study. The ONP-002 program is positioned to address a significant unmet medical need, as there are currently no FDA-approved pharmacological treatments for traumatic brain injuries, a condition affecting millions annually.

Looking ahead, Oragenics faces substantial challenges, including the need for additional capital to fund ongoing operations and clinical trials. The company has indicated that it may pursue various financing options, including equity and debt financing, to support its development activities. The management has expressed concerns regarding its ability to continue as a going concern, given the recurring losses and the need for significant funding to advance its product candidates. The company is also exploring strategic partnerships and licensing agreements to enhance its financial position and operational capabilities.